Trial Profile
A retrospective study evaluating the non-inferiority in controlling disease activity of an extended interval dosing (EID) of natalizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Oct 2018
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 25 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis